Market Trends

New listed company:Caliway Biopharmaceuticals Co., Ltd.(6919)

Yu-Tse Yao
Senior Associate at TWSE

<中文版>

Caliway Biopharmaceuticals Co., Ltd. was established in 2012, focusing on the development of new drugs for aesthetic medicine and chronic inflammatory diseases. Targeting a market exceeding $10 billion, it aims to develop drugs for conditions with inadequate existing treatments, significant side effects, or no approved therapies.

Unique Self-Developed New Drug Development Technology Platform

Caliway possesses a unique drug development technology platform that includes a lead compound-screening platform, a patented nanoparticle platform, a pharmacology and pharmacodynamics animal model platform, and a single dose & repeated dose toxicity study platform. This enables rapid and flexible research progress. Additionally, by adopting a multi-indication strategy for each candidate drug, Caliway targets at least two indications for development, which not only maximizes the market value of the drugs but also reduces risks associated with market changes and the R&D process.

Precision Selection Capability and Comprehensive Strategic Layout

To reduce risks and enhance the effectiveness of R&D licensing, Caliway employs a multi-indication strategy, ensuring that each candidate drug targets at least two indications. By differentiating treatment methods and formulations, the market value of new drugs is maximized. Consequently, when unforeseen market risks arise, Caliway’s operational team can swiftly adjust the product line to mitigate the risks associated with market fluctuations and the R&D process. For example, the drug CBL-514 has shown statistically significant efficacy in three entirely different indications and has the potential for future applications in other conditions related to excess fat or hyperplasia, thereby not only reducing risks but also increasing the future licensing and collaboration value of the product.

Figure1:Illustration of CBL-514 Applied to Non-surgical fat reduction Indications

Caliway’s core technologies and platforms can be applied interchangeably. Currently, four new drug products are under development: CBL-514, CBA-539, CBF-520, and CBO-012. Each product has different API and indications, placed at various stages of development based on their characteristics and current and future market demands, thus avoiding the pitfalls of a single product line. Although the indications differ, they all belong to the fields of aesthetic medicine or chronic inflammatory diseases, allowing for application in similar areas.

Future Plans and Vision

Looking ahead, Caliway will continue to address the unmet needs in aesthetic medicine and chronic inflammatory diseases, seeking drug candidates with niche market potential. The company plans to negotiate global licensing or acquisitions with major pharmaceutical firms and pursue regional sales authorizations in Taiwan, China, Korea, and Southeast Asian countries. Caliway aims to drive the development of the global aesthetic medicine industry, leading local fat reduction technology into a new era of full-body aesthetic treatments. The goal is to create another blockbuster drug with annual sales of $10 billion, offering more innovative treatment options and hope, enabling consumers worldwide to enjoy healthier, better, and more confident lives.

Figure2:Caliway Biotechnology R&D Team
Top